Currently available therapies for the treatment of chronic hepatitis C are effective in half of patients, but are expensive, often poorly tolerated, and unsuitable for certain patient populations. The ideal therapy would be highly effective, orally bioavailable, have minimal side effects, be cost ef
β¦ LIBER β¦
Future therapy of hepatitis C
β Scribed by John G. McHutchison; Keyur Patel
- Book ID
- 111722049
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 118 KB
- Volume
- 36
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Future therapy of hepatitis C
β
John G. McHutchison; Keyur Patel
π
Article
π
2002
π
John Wiley and Sons
π
English
β 850 KB
A glimpse at the future of hepatitis C t
β
Lei Y. Lim; Paul Y. Kwo
π
Article
π
2011
π
John Wiley and Sons
π
English
β 631 KB
Activation of hepatic stellate cells in response to chronic inflammation represents a crucial step in the development of liver fibrosis. However, the molecules involved in the interaction between immune cells and stellate cells remain obscure. Herein, we identify the chemokine CCL5 (also known as RA
Antiviral Resistance and the Future Land
β
Wyles, D. L.
π
Article
π
2013
π
University of Chicago Press
π
English
β 254 KB
Treatment of patients with genotype 3 ch
β
Shiv K. Sarin; Chandan K. N. Kumar
π
Article
π
2011
π
John Wiley and Sons
π
English
β 121 KB
Estimating the impact of hepatitis C vir
β
MarΓa Buti; RamΓ³n San Miguel; Max Brosa; Juan M. CabasΓ©s; Montserrat Medina; Mig
π
Article
π
2005
π
Elsevier Science
π
English
β 202 KB
Mechanisms of drug resistance to current
β
Jean-Michel Pawlotsky
π
Article
π
2004
π
Current Science Inc.
π
English
β 453 KB